– USA, GA – Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the election of Gilbert S. Omenn, M.D., Ph.D., to its Board of Directors, effective immediately. Dr. Omenn, a leading cancer researcher, is a professor of internal medicine, human genetics and public health, and director of the Center for Computational Medicine and Bioinformatics at the University of Michigan in Ann Arbor, Mich.
According to James Czirr, Executive Chairman of Galectin Therapeutics, “Gaining a new board member with Dr. Omenn’s Board of Director experience at Amgen between the time Amgen was an early stage company in 1987 and 2014, when it is clearly one of the great biotech success stories of all time, should prove extremely beneficial as we pursue the Galectin Therapeutics’ goal of becoming another great biotech success story.”
“We are extremely pleased to have Dr. Omenn join Galectin Therapeutics’ Board of Directors,” said Dr. Peter G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc. “As a renowned cancer researcher, Dr. Omenn has extraordinary experience in translational science. He will bring an invaluable wealth of knowledge for the Company as we advance our proprietary galectin-inhibiting compounds.”
Dr. Omenn served on the board of directors of Amgen Inc. for 27 years and of Rohm & Haas Company for 22 years. He currently serves on the boards of Esperion Therapeutics Inc., Etubics Corp.and Oncofusion Therapeutics Inc. He leads major research programs in proteomics and integrative biomedical informatics in his current position at the University of Michigan. Dr. Omenn served as executive vice president for medical affairs and as chief executive officer of the University of Michigan Health System from 1997 to 2002. Prior to this, he was the dean of the School of Public Health and Community Medicine and professor of medicine at the University of Washington. He is the author of 548 research papers and scientific reviews and author/editor of 18 books. Dr. Omenn received his B.A. summa cum laude from Princeton University, M.D. magna cum laude from Harvard Medical School, and Ph.D. in genetics from the University of Washington.
“Non-viral fibrotic disease of the liver, and of other organs, represents one of the major unmet needs for therapeutics. Galectin Therapeutics has developed a very promising carbohydrate-based strategy focused on galectin biology. Successful treatment of fibrosis will prevent grievous and costly complications, like cirrhosis and liver cancers,” said Dr. Omenn.
In addition to his role on the Board of Directors, Dr. Omenn will continue to serve on Galectin Therapeutics’ Scientific Advisory Board.
About Galectin Therapeutics
Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company’s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.